Literature DB >> 28516197

Optimized immunohistochemistry using the D5F3 antibody provides a reliable test for identification of ALK-positive lung adenocarcinomas.

Gian Luca Rampioni Vinciguerra1, Stefania Scarpino2, Benedetto Pini1, Claudia Cippitelli1, Flavio Fochetti1, Luigi Ruco1.   

Abstract

We used optimized immunohistochemistry (IHC) with the D5F3 antibody for detection of tumours in a prospective study of 307 pulmonary adenocarcinomas. Cases positive by IHC (1+, 2+, 3+) were further investigated by fluorescent in situ hybridization (FISH). Of 307 cases, 22 (7.2%) were moderately intensely positive (2+/3+); 18 of these (82%) were also positive by FISH. Of the four IHC-positive/FISH-negative cases, one was unsuitable for FISH and three had abnormalities of the ALK gene. All cases with weak reactivity with D5F3 (1+) were FISH-negative. The FISH positive/IHC-positive cases with moderately intense reactivity had the typical clinicopathologic features of ALK-positive patients (younger age, p < 0.01; higher frequency in metastatic sites, p < 0.01; cribriform/mucinous/signet histology, p < 0.01; stage IV disease, p < 0.01). In conclusion, our findings indicate that optimized IHC using the D5F3 antibody provides a reliable and inexpensive test for identification of ALK-positive adenocarcinomas. Inclusion of this information in the pathology report at the time of the histological diagnosis might significantly shorten time to treatment.

Entities:  

Keywords:  ALK; Adenocarcinoma; D5F3; Immunohistochemistry; Lung; Pulmonary

Mesh:

Substances:

Year:  2017        PMID: 28516197     DOI: 10.1007/s00428-017-2145-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  13 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.

Authors:  Antonio Marchetti; Alessia Di Lorito; Maria Vittoria Pace; Manuela Iezzi; Lara Felicioni; Tommaso D'Antuono; Giampaolo Filice; Luigi Guetti; Felice Mucilli; Fiamma Buttitta
Journal:  J Thorac Oncol       Date:  2016-02-22       Impact factor: 15.609

3.  EML4-ALK: honing in on a new target in non-small-cell lung cancer.

Authors:  Leora Horn; William Pao
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

4.  Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.

Authors:  Chris M J Conklin; Kenneth J Craddock; Cherry Have; Janessa Laskin; Christian Couture; Diana N Ionescu
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

5.  Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

Authors:  Christina I Selinger; Toni-Maree Rogers; Prudence A Russell; Sandra O'Toole; Poyee Yip; Gavin M Wright; Zoe Wainer; Lisa G Horvath; Michael Boyer; Brian McCaughan; Maija Rj Kohonen-Corish; Stephen Fox; Wendy A Cooper; Benjamin Solomon
Journal:  Mod Pathol       Date:  2013-06-07       Impact factor: 7.842

6.  Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.

Authors:  Lynette M Sholl; Stanislawa Weremowicz; Stacy W Gray; Kwok-Kin Wong; Lucian R Chirieac; Neal I Lindeman; Jason L Hornick
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

7.  An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.

Authors:  Murry W Wynes; Lynette M Sholl; Manfred Dietel; Ed Schuuring; Ming S Tsao; Yasushi Yatabe; Raymond R Tubbs; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2014-05       Impact factor: 15.609

8.  Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

Authors:  Scott J Rodig; Mari Mino-Kenudson; Sanja Dacic; Beow Y Yeap; Alice Shaw; Justine A Barletta; Hannah Stubbs; Kenny Law; Neal Lindeman; Eugene Mark; Pasi A Janne; Thomas Lynch; Bruce E Johnson; A John Iafrate; Lucian R Chirieac
Journal:  Clin Cancer Res       Date:  2009-08-11       Impact factor: 12.531

9.  ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.

Authors:  Greta Alì; Agnese Proietti; Serena Pelliccioni; Cristina Niccoli; Cristiana Lupi; Elisa Sensi; Riccardo Giannini; Nicla Borrelli; Maura Menghi; Antonio Chella; Alessandro Ribechini; Federico Cappuzzo; Franca Melfi; Marco Lucchi; Alfredo Mussi; Gabriella Fontanini
Journal:  Arch Pathol Lab Med       Date:  2014-06-02       Impact factor: 5.534

10.  A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.

Authors:  John Le Quesne; Manisha Maurya; Slaveya G Yancheva; Mary O'Brien; Sanjay Popat; Andrew C Wotherspoon; David Gonzalez de Castro; Andrew G Nicholson
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

View more
  2 in total

Review 1.  ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

Review 2.  Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

Authors:  Véronique Hofman; Sandra Lassalle; Coraline Bence; Elodie Long-Mira; Sacha Nahon-Estève; Simon Heeke; Virginie Lespinet-Fabre; Catherine Butori; Marius Ilié; Paul Hofman
Journal:  Cancers (Basel)       Date:  2018-03-13       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.